- Previous Close
4.4500 - Open
4.5800 - Bid 4.4000 x --
- Ask 4.2100 x --
- Day's Range
4.4400 - 4.5900 - 52 Week Range
3.7400 - 7.4600 - Volume
56,766 - Avg. Volume
165,511 - Market Cap (intraday)
368.043M - Beta (5Y Monthly) 1.25
- PE Ratio (TTM)
-- - EPS (TTM)
-2.1200 - Earnings Date Feb 24, 2025 - Feb 28, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Jan 18, 2023
- 1y Target Est
6.10
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. The company operates through three segments: Women's Health, Dermatology, and International. It provides oral drug delivery systems; and contract development and manufacturing services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.
www.maynepharma.com--
Full Time Employees
June 30
Fiscal Year Ends
Sector
Industry
Recent News: MYX.AX
View MorePerformance Overview: MYX.AX
Trailing total returns as of 1/14/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MYX.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MYX.AX
View MoreValuation Measures
Market Cap
368.04M
Enterprise Value
257.59M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.93
Price/Book (mrq)
0.81
Enterprise Value/Revenue
0.66
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-44.86%
Return on Assets (ttm)
-2.33%
Return on Equity (ttm)
-30.98%
Revenue (ttm)
388.4M
Net Income Avi to Common (ttm)
-168.62M
Diluted EPS (ttm)
-2.1200
Balance Sheet and Cash Flow
Total Cash (mrq)
149.28M
Total Debt/Equity (mrq)
8.55%
Levered Free Cash Flow (ttm)
59.83M